| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From The Washington Cancer Institute (FM, PM, OAS, PHS), Washington, DC; and Memorial Sloan-Kettering Cancer Center (MU), New York, New York.
Correspondence: Address correspondence and reprint requests to: Paul H. Sugarbaker, MD, FACS, FRCS, The Washington Cancer Institute, Washington Hospital Center, 110 Irving St., NW, Washington, DC 20010; Fax: 202-877-8602; E-mail: paul.sugarbaker{at}medstar.net
Background: Hyperthermia enhances the cytotoxicity of some chemotherapeutic agents. We have studied the effect of moderate hyperthermia (41.5°C) on the cytotoxicity of five new chemotherapeutic agents (docetaxel, paclitaxel, irinotecan, oxaliplatin, and gemcitabine) and melphalan against a spontaneous murine fibrosarcoma.
Methods: The tumor was an early-generation isotransplant of a spontaneous C3Hf/Sed mouse fibrosarcoma, FSa-II. Hyperthermia was administered by immersing the tumor-bearing foot into a constant temperature water bath set at 41.5°C for 30 minutes when the tumor reached 34 mm3. Chemotherapy was administered intraperitoneally immediately before hyperthermia. Tumor response was studied by the mean tumor growth time and the mean tumor growth delay time.
Results: Hyperthermia significantly increased the tumor growth times of the animals treated with docetaxel, irinotecan, and gemcitabine at low dose and these drugs plus oxaliplatin at high dose. Docetaxel at high dose showed the greatest control of tumor growth by hyperthermia, with a 26% reduction. Concerning the taxanes, paclitaxel cytotoxicity was not enhanced by hyperthermia, but docetaxel was enhanced by hyperthermia at both doses of drug.
Conclusions: Moderate hyperthermia increases the cytotoxicity of docetaxel, irinotecan, and gemcitabine on mouse fibrosarcoma. Paclitaxel did not show heat enhancement. Oxaliplatin and docetaxel showed greater heat enhancement when the drug dose was high.
Key Words: Hyperthermia • Intraperitoneal chemotherapy • Thermal enhancement • Animal tumors
This article has been cited by other articles:
 |
|
 |
|
  G. BARONZIO, A. GRAMAGLIA, and G. FIORENTINI Current Role and Future Perspectives of Hyperthermia for Prostate Cancer Treatment In Vivo, January 1, 2009; 23(1): 143 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. deBree, H. Rosing, D. Filis, J. Romanos, M. Melisssourgaki, M. Daskalakis, M. Pilatou, E. Sanidas, P. Taflampas, K. Kalbakis, et al. Cytoreductive Surgery and Intraoperative Hyperthermic Intraperitoneal Chemotherapy with Paclitaxel: A Clinical and Pharmacokinetic Study Ann. Surg. Oncol., April 1, 2008; 15(4): 1183 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Michalakis, S. D. Georgatos, E. de Bree, H. Polioudaki, J. Romanos, V. Georgoulias, D. D. Tsiftsis, and P. A. Theodoropoulos Short-Term Exposure of Cancer Cells to Micromolar Doses of Paclitaxel, with or without Hyperthermia, Induces Long-Term Inhibition of Cell Proliferation and Cell Death In Vitro Ann. Surg. Oncol., March 1, 2007; 14(3): 1220 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Sugarbaker, J. T. Mora, P. Carmignani, O. A. Stuart, and D. Yoo Update on Chemotherapeutic Agents Utilized for Perioperative Intraperitoneal Chemotherapy Oncologist, February 1, 2005; 10(2): 112 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Elias, T. Matsuhisa, L. Sideris, G. Liberale, L. Drouard-Troalen, B. Raynard, M. Pocard, J. M. Puizillou, V. Billard, P. Bourget, et al. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance Ann. Onc., October 1, 2004; 15(10): 1558 - 1565. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
